Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
golocdacimab
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Golocdacimab (MEDI6570) is a fully human monoclonal antibody that targets the lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1). By blocking LOX-1, it inhibits the binding of oxidized LDL and other modified lipids to this scavenger receptor. The drug was developed for potential use in cardiovascular diseases such as atherosclerosis and coronary disorders, with additional research interest in type 2 diabetes. Its mechanism of action involves dose-dependent suppression of soluble LOX-1 levels, which may reduce inflammatory and lipid risk factors associated with atherosclerosis. Golocdacimab was developed by MedImmune/AstraZeneca but has been discontinued in clinical development for its primary indications[1][2][4][5][6].
- Other names
- golocdacimab
02
Targets
OLR1 (Lectin-like oxidized LDL receptor-1)
Beyond the preview
Go deeper on golocdacimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on golocdacimab.